Research analysts at Barclays boosted their price target on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) from $70.00 to $75.00 in a report released on Friday, American Banking News.com reports. The firm currently has an “overweight” rating on the stock. Barclays’ price target points to a potential upside of 8.76% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Wells Fargo & Co. reiterated a “market perform” rating on shares of BioMarin Pharmaceutical in a research note to investors on Friday, September 27th. Separately, analysts at Wedbush reiterated a “hold” rating on shares of BioMarin Pharmaceutical in a research note to investors on Friday, September 20th. They now have a $88.00 price target on the stock. Finally, analysts at William Blair reiterated a “hold” rating on shares of BioMarin Pharmaceutical in a research note to investors on Wednesday, September 18th. They now have a $88.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $72.95.
BioMarin Pharmaceutical (NASDAQ:BMRN) traded down 4.19% on Friday, hitting $66.07. 2,107,180 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 52 week low of $36.28 and a 52 week high of $76.34. The stock has a 50-day moving average of $66.1 and a 200-day moving average of $62.93. The company’s market cap is $9.257 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings data on Thursday, October 24th. The company reported ($0.38) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.30) by $0.08. The company had revenue of $136.90 million for the quarter, compared to the consensus estimate of $140.00 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, analysts predict that BioMarin Pharmaceutical will post $-1.15 earnings per share for the current fiscal year.
In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime unloaded 2,000 shares of BioMarin Pharmaceutical stock on the open market in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $67.73, for a total transaction of $135,460.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.